JP2017519501A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017519501A5 JP2017519501A5 JP2016573833A JP2016573833A JP2017519501A5 JP 2017519501 A5 JP2017519501 A5 JP 2017519501A5 JP 2016573833 A JP2016573833 A JP 2016573833A JP 2016573833 A JP2016573833 A JP 2016573833A JP 2017519501 A5 JP2017519501 A5 JP 2017519501A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- axl
- domain
- seq
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1410826.0A GB201410826D0 (en) | 2014-06-18 | 2014-06-18 | Anti-axl antibodies |
| GB1410826.0 | 2014-06-18 | ||
| PCT/EP2015/063700 WO2015193428A1 (en) | 2014-06-18 | 2015-06-18 | Anti-axl antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017519501A JP2017519501A (ja) | 2017-07-20 |
| JP2017519501A5 true JP2017519501A5 (en:Method) | 2018-05-10 |
| JP6787795B2 JP6787795B2 (ja) | 2020-11-18 |
Family
ID=51266761
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016573833A Active JP6787795B2 (ja) | 2014-06-18 | 2015-06-18 | 抗Ａｘｌ抗体 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US9975954B2 (en:Method) |
| EP (1) | EP3157559B1 (en:Method) |
| JP (1) | JP6787795B2 (en:Method) |
| KR (1) | KR102453226B1 (en:Method) |
| CN (2) | CN106573979B (en:Method) |
| AU (1) | AU2015276153B2 (en:Method) |
| CA (1) | CA2952296A1 (en:Method) |
| DK (1) | DK3157559T3 (en:Method) |
| GB (1) | GB201410826D0 (en:Method) |
| HR (1) | HRP20201091T1 (en:Method) |
| HU (1) | HUE049755T2 (en:Method) |
| LT (1) | LT3157559T (en:Method) |
| MX (1) | MX388222B (en:Method) |
| SI (1) | SI3157559T1 (en:Method) |
| WO (1) | WO2015193428A1 (en:Method) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201410826D0 (en) * | 2014-06-18 | 2014-07-30 | Bergenbio As | Anti-axl antibodies |
| GB201410825D0 (en) | 2014-06-18 | 2014-07-30 | Bergenbio As | Anti-axl antibodies |
| ES2764299T3 (es) * | 2014-12-09 | 2020-06-02 | Inst Nat Sante Rech Med | Anticuerpos monoclonales humanos contra AXL |
| WO2016097370A2 (en) * | 2014-12-18 | 2016-06-23 | Bergen Teknologioverføring As | Anti-axl antagonistic antibodies |
| GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
| GB201509338D0 (en) * | 2015-05-29 | 2015-07-15 | Bergenbio As | Combination therapy |
| GB201610902D0 (en) | 2016-06-22 | 2016-08-03 | Bergen Teknologioverforing As And Bergenbio As | Anti-Axl Antagonistic Antibodies |
| JP6671555B2 (ja) * | 2017-02-08 | 2020-03-25 | アーデーセー セラピューティクス ソシエテ アノニム | ピロロベンゾジアゼピン抗体複合体 |
| US20210215697A1 (en) * | 2018-05-14 | 2021-07-15 | Bergenbio Asa | Serum Biomarkers |
| CN110540592B (zh) * | 2018-05-29 | 2022-08-09 | 杭州尚健生物技术有限公司 | 结合axl蛋白的抗体及其应用 |
| US20220177593A1 (en) * | 2019-03-29 | 2022-06-09 | Celldex Therapeutics, Inc. | Anti-axl antibodies and methods of use thereof |
| GB201912059D0 (en) | 2019-08-22 | 2019-10-09 | Bergenbio As | Combaination therapy of a patient subgroup |
| CN113045664B (zh) * | 2019-11-28 | 2023-05-12 | 尚健单抗（北京）生物技术有限公司 | 一种分离的结合抗原axl的蛋白及其用途 |
| WO2021154156A1 (en) * | 2020-01-31 | 2021-08-05 | Agency For Science, Technology And Research | Anti-axl antibody and uses thereof |
| GB202004189D0 (en) | 2020-03-23 | 2020-05-06 | Bergenbio As | Combination therapy |
| IL297132A (en) | 2020-04-08 | 2022-12-01 | Bergenbio Asa | axl inhibitors for antiviral therapy |
| GB202006072D0 (en) | 2020-04-24 | 2020-06-10 | Bergenbio Asa | Method of selecting patients for treatment with cmbination therapy |
| AU2022211971A1 (en) | 2021-01-29 | 2023-08-10 | Illimis Therapeutics, Inc. | Fusion molecule having non-inflammatory phagocytosis inducing activity |
| GB202104037D0 (en) | 2021-03-23 | 2021-05-05 | Bergenbio Asa | Combination therapy |
| IL289525B2 (en) * | 2021-12-30 | 2023-03-01 | B G Negev Technologies And Applications Ltd At Ben Gurion Univ | Conjugated antibodies for cancer treatment |
| CN116348497B (zh) * | 2023-01-05 | 2023-11-17 | 浙江时迈药业有限公司 | 针对axl的抗体及其用途 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6884879B1 (en) * | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| CL2007002668A1 (es) * | 2006-09-20 | 2008-05-09 | Amgen Inc | Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2. |
| MY155621A (en) * | 2007-11-12 | 2015-11-13 | U3 Pharma Gmbh | Axl antibodies |
| AU2008321835B2 (en) | 2007-11-15 | 2014-11-20 | Chugai Seiyaku Kabushiki Kaisha | Monoclonal antibody capable of binding to anexelekto, and use thereof |
| EP2198884A1 (en) * | 2008-12-18 | 2010-06-23 | Centre National de la Recherche Scientifique (CNRS) | Monoclonal antibodies directed against LG4-5 domain of alpha3 chain of human laminin-5 |
| EP2270053A1 (en) * | 2009-05-11 | 2011-01-05 | U3 Pharma GmbH | Humanized AXL antibodies |
| TW201041595A (en) * | 2009-05-15 | 2010-12-01 | Chugai Pharmaceutical Co Ltd | Anti-axl antibody |
| TW201106972A (en) * | 2009-07-27 | 2011-03-01 | Genentech Inc | Combination treatments |
| CA2794731C (en) | 2010-06-18 | 2019-03-19 | Genentech, Inc. | Anti-axl antibodies and methods of use |
| CA2839508A1 (en) * | 2011-06-22 | 2012-12-27 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Anti-axl antibodies and uses thereof |
| US9409988B2 (en) | 2011-06-22 | 2016-08-09 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Anti-Axl antibodies and uses thereof |
| EP2589609A1 (en) | 2011-11-03 | 2013-05-08 | Pierre Fabre Medicament | Antigen binding protein and its use as addressing product for the treatment of cancer |
| GB201410825D0 (en) | 2014-06-18 | 2014-07-30 | Bergenbio As | Anti-axl antibodies |
| GB201410826D0 (en) * | 2014-06-18 | 2014-07-30 | Bergenbio As | Anti-axl antibodies |
| WO2016097370A2 (en) * | 2014-12-18 | 2016-06-23 | Bergen Teknologioverføring As | Anti-axl antagonistic antibodies |
| GB201506411D0 (en) * | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
| MX2019012464A (es) * | 2017-04-20 | 2019-12-11 | Adc Therapeutics Sa | Terapia combinada con un conjugado de anticuerpo y farmaco anti-axl. |
-
2014
- 2014-06-18 GB GBGB1410826.0A patent/GB201410826D0/en not_active Ceased
-
2015
- 2015-06-18 HR HRP20201091TT patent/HRP20201091T1/hr unknown
- 2015-06-18 JP JP2016573833A patent/JP6787795B2/ja active Active
- 2015-06-18 EP EP15729504.9A patent/EP3157559B1/en active Active
- 2015-06-18 DK DK15729504.9T patent/DK3157559T3/da active
- 2015-06-18 SI SI201531303T patent/SI3157559T1/sl unknown
- 2015-06-18 AU AU2015276153A patent/AU2015276153B2/en not_active Ceased
- 2015-06-18 CN CN201580042717.5A patent/CN106573979B/zh active Active
- 2015-06-18 CA CA2952296A patent/CA2952296A1/en active Pending
- 2015-06-18 LT LTEP15729504.9T patent/LT3157559T/lt unknown
- 2015-06-18 HU HUE15729504A patent/HUE049755T2/hu unknown
- 2015-06-18 MX MX2016016883A patent/MX388222B/es unknown
- 2015-06-18 KR KR1020177001482A patent/KR102453226B1/ko active Active
- 2015-06-18 CN CN202110689921.3A patent/CN113563471B/zh active Active
- 2015-06-18 WO PCT/EP2015/063700 patent/WO2015193428A1/en not_active Ceased
- 2015-06-18 US US15/318,028 patent/US9975954B2/en active Active
-
2018
- 2018-04-20 US US15/958,076 patent/US11186643B2/en not_active Expired - Fee Related
-
2021
- 2021-10-18 US US17/503,568 patent/US20220185897A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017519501A5 (en:Method) | ||
| JP2017526339A5 (en:Method) | ||
| US12312410B2 (en) | Anti-CD39 antibodies | |
| JP2018506961A5 (en:Method) | ||
| JP2021008487A (ja) | 抗ｎｋｇ２ａ抗体を使用した治療計画 | |
| CN102741282B (zh) | 针对转铁蛋白受体的抗体以及其用于依赖于铁的肿瘤的免疫疗法的用途 | |
| JP2017535257A5 (en:Method) | ||
| IL276950B1 (en) | Anti-cd73 antibodies and uses thereof | |
| JP6608698B2 (ja) | Ｐ２ｘ７受容体アンタゴニスト及びアゴニスト | |
| JP2017522903A5 (en:Method) | ||
| WO2020011970A1 (en) | Anti-mesothelin antibodies | |
| JP2017529838A5 (en:Method) | ||
| JP2013527761A5 (en:Method) | ||
| AU2020212534B2 (en) | High affinity monoclonal antibodies targeting glypican-1 and methods of use | |
| JP2021501744A5 (en:Method) | ||
| JP2020537520A5 (en:Method) | ||
| JP2020534830A5 (en:Method) | ||
| HRP20180352T1 (hr) | Protutijela anti-fcrh5 | |
| JP2018500014A5 (en:Method) | ||
| JP2017530692A5 (en:Method) | ||
| JP2016536342A5 (en:Method) | ||
| JP2019534705A5 (en:Method) | ||
| JP2012521217A5 (en:Method) | ||
| KR20230016186A (ko) | 갈렉틱-3 차단에 의한 염증성 질환의 치료 방법 | |
| JP2013519364A5 (en:Method) |